AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00796692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadroparin
Description: LMWH is given with a weight adjusted dose of 86 international anti-factor Xa units of nadroparin (Fraxiparine) per kilogram of body weight(86 anti-factor Xa IU/kg) subcutaneously every 12 hours,which will be used at least 5-7 days.
Study NCT00796692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated heparin(UFH)
Description: UFH is received with an initial bolus dose of 80 IU per kilogram, followed by a continuous intravenous infusion at an initial rate of 18 IU per kilogram per hour. The dose is subsequently adjusted so that the activated partial thromboplastin time (APTT) would be 1.5 to 2.5 times the control value in normal subjects. The tests are performed 4 hours after the start of treatment, whenever a sub-therapeutic APTT had been measured after a dose adjustment, and otherwise daily.UFH will be used at least 5-7 days.
Study NCT01172002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Leflunomide, 20 mg/d, ORAL ,each day. Number of Cycles: until progression or unacceptable toxicity develops.~Predonine, 10 mg/d, ORAL, each day. If extra renal flare occurs, the dose of predonine may be increased to 1mg/kg/day for not more than 2 weeks.
Study NCT01172002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: Azathioprine,50-100 mg/d, ORAL ,each day . Number of Cycles: until progression or unacceptable toxicity develops.~Predonine, 10 mg/d, ORAL, each day. If extra renal flare occurs, the dose of predonine may be increased to 1mg/kg/day for not more than 2 weeks.
Study NCT00119548 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Rates of HIV testing and receipt of results
Description: Rates of HIV testing and receipt of results
Study NCT00119548 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sexual risk reduction; HIV knowledge improvement
Description: Sexual risk reduction; HIV knowledge improvement
Study NCT04499651 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Navigation
Description: Trained study navigators will provide one-on-one learning sessions and accompaniments to criminal-justice involved people to help link them to HIV/Hepatitis C care
Study NCT04266379 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop insulin infusion driven by continuous glucose monitoring through an algorithm, in free-life conditions
Description: Continuous subcutaneous insulin infusion according to an automated algorithm from continuous glucose monitoring data
Study NCT04266379 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Subcutaneous Insulin Infusion and Continuous Glucose Monitoring
Description: Insulin delivered subcutaneously by a pump and manage by the patient with the help of a CGM sensor
Study NCT02982005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4827
Description: Administered KHK4827 by subcutaneous (SC) injection until week 62.
Study NCT02982005 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered placebo by subcutaneous (SC) injection until week 12. Administered KHK4827 by SC injection from week 13 until week 62.
Study NCT01530230 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: oxytocin
Description: Intravenous bolus dose given during 1 minute after clamping of the umbilical cord
Study NCT04679090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: Participants will exercise twice a week for twelve weeks total.
Study NCT02609165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhNGF 180 µg/ml eye drops solution
Description: eye drops
Study NCT02609165 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle eye drops
Description: placebo
Study NCT02336997 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FAT-GRAFT
Description: Liposuction will be performed and autologous fat graft will be harvest after washing with saline. Patients will receive autologous fat graft transplantation subdermally to expanded skin at the density of 0.1 ml/cm2.
Study NCT02336997 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SVF-TRANSPLANTATION
Description: Liposuction will be performed. SVF will be separated from autologous fat graft by collagenase digestion. Patients will receive resuspended SVF transplantation subdermally to expanded skin at the density of 1\*10e6 cells/cm2.
Study NCT02336997 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Saline will be injected into expanded skin.
Study NCT02449291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD421
Study NCT06473662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral insulin
Description: Capsule administered by mouth with a glass of water two times per day, once before breakfast and once before supper
Study NCT02449291 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02316964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: 20 mg/m2 Given IV (intravenous) for 5 days over 60 minutes
Study NCT02316964 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: natural killer cell therapy
Description: Undergo infusion of allogeneic NK cells on day 0
Study NCT02316964 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given SC
Study NCT02316964 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03220243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC-AFP
Description: Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cells.
Study NCT04767867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-oxygenation
Description: Induction of anaesthesia after 2mins 45 seconds of pre-oxygenation with 1-1.5mcg/kg remifentanil plus 2-3mg/kg propofol. Propofol (10mg/kg/hr) and remifentanil (0.15mcg/kg/min) infusions commenced until study conclusion.~Positive pressure ventilation commenced at Sp02 92%. Failure to intubate the patient during the first minute of apnoea results in withdrawal from the study.~Blood samples obtained from an arterial catheter immediately prior to commencing pre-oxygenation, after 90 and 180 seconds of pre-oxygenation, after one minute of apnoea, and every two minutes during the apnoeic period.
Study NCT04767867 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pre-oxygenation
Description: Induction of anaesthesia after 2mins 45 seconds of pre-oxygenation with 1-1.5mcg/kg remifentanil plus 2-3mg/kg propofol. Propofol (10mg/kg/hr) and remifentanil (0.15mcg/kg/min) infusions commenced until study conclusion.~Positive pressure ventilation commenced at Sp02 92%. Failure to intubate the patient during the first minute of apnoea results in withdrawal from the study.~Blood samples obtained from an arterial catheter immediately prior to commencing pre-oxygenation, after 90 and 180 seconds of pre-oxygenation, after one minute of apnoea, and every two minutes during the apnoeic period.
Study NCT04439292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib Mesylate
Description: Given PO
Study NCT04439292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib Dimethyl Sulfoxide
Description: Given PO
Study NCT01457911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride and Metformin hydrochloride combination (HOE490)
Description: Pharmaceutical form:tablet Route of administration: oral
Study NCT01457911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride (HOE490)
Description: Pharmaceutical form:tablet Route of administration: oral
Study NCT02934620 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CSD500 Condom
Description: CSD500 is a commercial condom that complies fully with the requirements of ISO 4074, the international standard for male latex condoms. The product is designed to increase sexual pleasure.
Study NCT02934620 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Condom
Description: The standard condom is a standard condom in Vietnam at the time of the study. It is provided for pregnancy and disease prevention.
Study NCT02934620 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Condom Counseling
Description: The intervention arm will receive counseling that briefly addresses condom's dual protection against pregnancy and HIV/STI but that otherwise emphasizes the potential for increased sexual pleasure with CSD500 use. Counseling to this arm also will include CSD500-specific instructions, such as the need to briefly massage the gel inside the condom teat onto the penis head after donning the condom and to not use multiple condoms within a 24-hour period. The control arm will receive standard counseling to use condoms for pregnancy and disease prevention without receiving any messages about the use of condoms for sexual pleasure.
Study NCT02934620 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Condom Counseling
Description: The intervention arm will receive counseling that briefly addresses condom's dual protection against pregnancy and HIV/STI but that otherwise emphasizes the potential for increased sexual pleasure with CSD500 use. Counseling to this arm also will include CSD500-specific instructions, such as the need to briefly massage the gel inside the condom teat onto the penis head after donning the condom and to not use multiple condoms within a 24-hour period. The control arm will receive standard counseling to use condoms for pregnancy and disease prevention without receiving any messages about the use of condoms for sexual pleasure.
Study NCT02234674 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Current intensive CDP
Description: Standard Intensive CDP including~* manual lymph drainage,~* pressotherapy and~* bandaging
Study NCT02234674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intensive CDP where Stendo pulsating suit replaces pressotherapy
Description: The intervention consist to perform daily during 5 days an intensive CDP where pressotheray is replaced by Stndo pulsating suit sessions.
Study NCT01121042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: 8mg per day oral capsule
Study NCT01121042 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily oral capsule matched to active study medication. Made form 100% lactose powder
Study NCT04215042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium chloride infusion
Study NCT04215042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium chloride infusion
Study NCT03219840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xylitol only chewing gum
Description: All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated.
Study NCT01548911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemtuzumab ozogamicin
Description: Given IV
Study NCT03934736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEPLISAV-B®
Description: HEPLISAV-B®, a licensed, commercially-available hepatitis B vaccine for adults 18 years of age and older, consisting of the adjuvant cytidine phosphoguanosine (CpG) 1018 combined with the antigen recombinant hepatitis B surface antigen (rHBsAg).
Study NCT00944502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Group A: Vitatonus DEXA injectable:~1 ampoule intramuscularly every 3 days for 10 days.~Group B: Vitatonus DEXA tablets:~1 tablet orally every 8 hours for 10 days.~Group C: Dexamethasone Injectable:~1 ampoule intramuscularly every 3 days for 10 days.~Group D: Dexamethasone tablets:~1 tablet orally every 8 hours for 10 days.
Study NCT00944502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Group A: Vitatonus DEXA injectable:~1 ampoule intramuscularly every 3 days for 10 days.~Group B: Vitatonus DEXA tablets:~1 tablet orally every 8 hours for 10 days.~Group C: Dexamethasone Injectable:~1 ampoule intramuscularly every 3 days for 10 days.~Group D: Dexamethasone tablets:~1 tablet orally every 8 hours for 10 days.
Study NCT01548911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02780713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9496 (Reference)
Description: AZD9496 (Reference)
Study NCT03238300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: N-Acetylcysteine; 600mg capsules by mouth, two pills twice daily (total 2400 mg/day). Participants will undergo MRI (including magnetic resonance imaging and functional MRI during an alcohol cue reactivity task) at baseline, after 10 days of N-Acetylcysteine and after 10 days of placebo.
Study NCT03238300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Capsule
Description: N-acetylcysteine-matched placebo tablet two pills twice daily. Participants will undergo MRI (including magnetic resonance imaging and functional MRI during an alcohol cue reactivity task) at baseline, after 10 days of N-Acetylcysteine and after 10 days of placebo.
Study NCT00990639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: candesartan for hepatic fibrosis
Description: Candesartan group(42 patients): oral candesartan at a daily dose of 8 mgin addition to ursodeoxycholic acid (UDCA, 600 mg/day) for 6 months.~UDCA group(43 patients): oral ursodeoxycholic acid (UDCA, 600 mg/day) only for 6 months
Study NCT00990639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: candesartan for hepatic fibrosis
Description: Candesartan group(42 patients): oral candesartan at a daily dose of 8 mgin addition to ursodeoxycholic acid (UDCA, 600 mg/day) for 6 months.~UDCA group(43 patients): oral ursodeoxycholic acid (UDCA, 600 mg/day) only for 6 months
Study NCT01860703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone
Description: Ferriprox 500 mg tablets
Study NCT01860703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deferiprone matching placebo tablets
Description: deferiprone matching placebo tablets
Study NCT01860703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin
Description: Active control
Study NCT01860703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: moxifloxacin-matching placebo
Study NCT00778479 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sepraspray
Description: Max. 10g of Sepraspray
Study NCT01584765 — intervention group
Intervention type: DRUG
Intervention: Prescription drugs with known hepatotoxicity
Description: 14 prescription drugs with known hepatotoxicity : Amoxicillin/clavulanate, nitrofurantoin, isoniazid, trimethoprim-sulfamethoxazole, duloxetine, valproate, interferon-beta, ciprofloxacin, lamotrigine, phenytoin, diclofenac, terbinafine, levofloxacin, aripiprazole
Study NCT02119910 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology Supported Manual
Study NCT01093079 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic partial nephrectomy
Description: Laparoscopic partial nephrectomy
Study NCT01093079 — intervention group
Intervention type: PROCEDURE
Intervention: Open partial nephrectomy
Description: Open partial nephrectomy
Study NCT01292109 — intervention group
Intervention type: DRUG
Intervention: sodium picosulphate
Description: Sodium picosulphate (PICOPREP®) taken by participant prior to X-ray examination, endoscopy or surgery.
Study NCT03365076 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Aerobic physical activity as stated in Arm A
Study NCT04730622 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SARC-F questionnaire
Description: Assessment of muscle performance based on self-reported information about grip strength, assistance with walking, rising from a chair, climbing stairs, and falls.
Study NCT04730622 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bone tissue histology
Description: Assessment of histomorphology and matrix-structure of tissue samples obtained from the bone resected during the hip prosthesis positioning.
Study NCT04730622 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Muscle tissue histology
Description: Assessment of histomorphology and ultrastructure of muscle biopsies taken from the upper portion of the vastus lateralis muscle, which is accessed in the surgical procedure of hip replacement.
Study NCT04730622 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Myostatin serum levels
Description: Quantification of circulating myostatin, a muscle-specific biomarker that suppresses muscle growth and bone formation.
Study NCT04730622 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Insulin-like growth factor 1 (IGF-1) serum levels
Description: Quantification of circulating IGF-1, a growth factor that promotes muscle growth and osteogenesis.
Study NCT04730622 — intervention group
Intervention type: OTHER
Intervention: Frequency food questionnaire
Description: Assessment of dietary habits based on self-reported information about the monthly- weekly- or daily-frequency consumption of main food groups, including cereals and bread, meat, fish, fruit, vegetable, legumes, dairy products, sweets and snacks, drinks, and dietary supplements.
Study NCT04730622 — intervention group
Intervention type: OTHER
Intervention: Gut microbiota profiling
Description: Assessment of gut microbiome composition on stool samples.
Study NCT00818961 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: alemtuzumab
Description: 43 mg subcutaneously over 3 days (3 mg on day -11, 10 mg on day -10, 30 mg on day -9)
Study NCT00818961 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: graft-versus-tumor induction therapy
Description: curative potential of allogeneic transplant results from the immune anti-tumor effect of donor cells or GVT/GVL
Study NCT00818961 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: rituximab
Description: in patients with Cd20+ malignancies: rituximab 375 mg/m\*2 day -13. rituximab 1000 mg/m\*2 on days, -6, +1, +8.
Study NCT00818961 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: busulfan
Description: For patients with AML, CML, MDS, MPS and ALL only: IV or oral busulfan may be given IV busulfan: 130 mg/m2 over 3 hours once daily on days -6, -5, -4 and -3 Oral busulfan: taken every 6 hours x 15 doses beginning on day -7 at 6pm and continuing through day -3 at 6am. 1 mg/kg test dose will be given prior to day -7 and PK samples will be drawn to calculate AUC.
Study NCT04682275 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Psychological measurements
Description: A questionnaire test (Beck depression Inventory) for depression was performed.
Study NCT02866175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: Edoxaban 60 mg once-daily or 30 mg once-daily in selected subjects
Study NCT02866175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel 75 mg once-daily
Study NCT02866175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 75 mg once-daily
Study NCT02866175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: prasugrel 5mg or 10 mg once-daily
Study NCT02866175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: prasugrel 5mg or 10 mg once-daily
Study NCT02866175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: ticagrelor 90 mg twice-daily
Study NCT02866175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: ticagrelor 90 mg twice-daily
Study NCT02866175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K antagonist
Description: VKA once-daily dosing for target international normalized ratio between 2.0 and 3.0, inclusive
Study NCT01584336 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LATG
Description: 1. After laparoscopic observation, the surgeon must check the possibility of laparoscopic surgery (without the serosal invasion of cancer or peritoneal metastasis or lymph node metastasis to splenic hilum). If the gastric cancer with serosal invasion or grossly lymph node metastasis to splenic hilum, operator must convert the operation method to open gastrectomy~2. The operator undergoes the laparoscopic total gastrectomy with lymph node dissection(including the status of lymph nodes - No #1,2,3,4sa,4sb,4d,5,6,7,8a,9,11p and 11d, and/or 12a).~3. The operator can choose any reconstruction method of esophagojejunostomy according to surgeon's preference.~4. After then, the operator performs the jejunojejunostomy.
Study NCT02780713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9496 Variant A
Description: AZD9496 Variant A.
Study NCT02780713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9496 Variant B
Description: AZD9496 Variant B
Study NCT02780713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9496 Variant C
Description: AZD9496 Variant C
Study NCT02780713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9496 Variant D
Description: AZD9496 Variant D
Study NCT01120015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diacerein
Description: Diclofenac sodium 75mg sustained release tablet once daily was given to both groups for 3 months. Capsule diacerein 50mg in study group and matched placebo in control group were given once daily for first month and twice daily for next two months with the main meals.